# Protocol for a cluster randomised controlled trial comparing structured Follow-up And Monitoring Of new USers of NHS hearing aids to usual care: the FAMOUS trial

**Authors:** Kevin J. Munro, Christopher Armitage, Rachel Elliott, Gabrielle H. Saunders, Rebecca Haydock, Ted Leverton, Edmund Juszczak, Francesca Oliver, Christopher Partlett, Caroline Rick, Anne Schilder, Jane Wild, Paul Wilson, Magdalena Sereda, Michael Loughran, Grace Holt, Bethany Gill

PMC · DOI: 10.1186/s13063-025-09188-9 · Trials · 2025-11-05

## TL;DR

This study tests if structured follow-up care improves hearing aid use and quality of life for NHS patients compared to usual care.

## Contribution

The trial introduces a structured follow-up model with behavior change interventions for new hearing aid users in the NHS.

## Key findings

- Structured follow-up care may improve hearing aid use compared to usual care.
- The trial includes process and economic evaluations to assess intervention feasibility and cost-effectiveness.

## Abstract

Hearing loss is a prevalent condition that impacts on social, mental and physical health, and has a significant economic burden. Hearing aids can improve the quality of life for those living with hearing loss; however, low and inconsistent use remains common. Within the National Health Service (NHS), follow-up care for new hearing aid users is highly variable and often lacks structure, which may contribute to low use. The FAMOUS trial investigates whether a structured care model for follow-up, combined with evidence-based behaviour change interventions, improves hearing aid use compared to usual care.

FAMOUS is a multi-centre, two-arm parallel-group cluster randomised controlled trial (CRCT) with integral internal pilot, economic, and process evaluations. The trial involves 36 NHS audiology services and compares two types of follow-up for new adult hearing aid users: structured care, which includes personalised action plans, early monitoring, and routine follow-up at 6 weeks post-fitting, to usual care, which includes the offer of a follow-up 6–12 weeks after fitting. Recruitment is conducted through participating services over 3 months, with pseudo-anonymised routine data collected from electronic medical records of all patients who attend. Consent and outcomes are then collected from patients at 12 weeks post-fitting. For patients who provide consent to future contact, the primary outcome (self-reported daily hearing aid use) is collected at 12 months post-fitting. Secondary outcomes (quality-of-life (QoL), hearing-related disability, and economic measures) are collected at both timepoints. Qualitative interviews with a subset of patients and hearing professionals in the intervention arm will assess the acceptability and implementation of the intervention. Statistical analyses, including mixed-effects regression modelling, will be conducted under an intention-to-treat framework.

FAMOUS addresses a critical evidence gap regarding the potential benefits of follow-up care for new hearing aid users. If the intervention is successful, it can be rolled out nationally using existing facilities with limited impact on resources, identified in the economic analysis, and would improve hearing aid use and quality of life for those living with hearing loss.

Prospectively registered with the International Standard Randomised Controlled Trial Number (ISRCTN) 10589817. Date of registration: 01/09/2022.

## Linked entities

- **Diseases:** hearing loss (MONDO:0005365)

## Full-text entities

- **Diseases:** hearing-related disability (MESH:D006311), Hearing loss (MESH:D034381)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12590654/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12590654/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12590654/full.md

---
Source: https://tomesphere.com/paper/PMC12590654